# EDGAR Filing Document

**Accession Number:** 0001494650
**File Stem:** 0001104659-25-055361
**Filing Date:** 2025-6
**Character Count:** 3202
**Document Hash:** 862109ab1f8821b27d7ea1cce0161ef1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-055361.hdr.sgml**: 20250602

**ACCESSION NUMBER**: 0001104659-25-055361

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250602

**DATE AS OF CHANGE**: 20250602

**EFFECTIVENESS DATE**: 20250602

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OptiNose, Inc.
- **CENTRAL INDEX KEY:** 0001494650
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 421771610
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38241
- **FILM NUMBER:** 251014195

**BUSINESS ADDRESS:**
- **STREET 1:** 777 TOWNSHIP LINE ROAD
- **STREET 2:** SUITE 300
- **CITY:** YARDLEY
- **STATE:** PA
- **ZIP:** 19067
- **BUSINESS PHONE:** 267-364-3500

**MAIL ADDRESS:**
- **STREET 1:** 777 TOWNSHIP LINE ROAD
- **STREET 2:** SUITE 300
- **CITY:** YARDLEY
- **STATE:** PA
- **ZIP:** 19067

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549**

------

**FORM 15** 

------

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.**

**Commission File Number 001-38241**

------

**OPTINOSE, INC.**

**(Exact name of registrant as specified in its charter)** 

------

**777 Township Line Road, Suite 300**

**Yardley, Pennsylvania 19067**

**(267) 364-3500**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)**

**Common stock, par value $0.001 per share**

**(Title of each class of securities covered by this Form)**

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
| Rule 12g-4(a)(1) | x |
| Rule 12g-4(a)(2) | ◻ |
| Rule 12h-3(b)(1)(i) | ⌧ |
| Rule 12h-3(b)(1)(ii) | ◻ |
| Rule 15d-6 | ◻ |
| Rule 15d-22(b) | ◻ |

---

Approximate number of holders of record as of the certification or notice date: One\*

\*Explanatory Note: Effective as of May 21, 2025, pursuant to that certain Agreement and Plan of Merger, dated as of March 19, 2025 by and among Paratek Pharmaceuticals, Inc. ("<u>Paratek</u>"), Orca Merger Sub, Inc. ("<u>Merger Sub</u>") and OptiNose, Inc. (the "<u>Company</u>"), Merger Sub merged with and into the Company, with the Company surviving such merger as a wholly owned subsidiary of Paratek.

Pursuant to the requirements of the Securities Exchange Act of 1934, OptiNose, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **OPTINOSE, INC.** | **OPTINOSE, INC.** |
| Date: June 2, 2025 | By: | /s/ Evan Loh |
|  | Name: | Evan Loh, M.D. |
|  | Title: | Chief Executive Officer |

---